News About: R&D
New drug 2 items go to Market in the first half of a year
New drug 2 items go to Market in the first half of a year
: Daewoong's EGF, Dongwha's DW166HC
In succession of SK Chemical's anti-cancer drug Sunpla 50mg (SK12053R) with platinum, Korean new drug 2 items are expe...
Choongwae. transfer new medicine on $ 7 million.
Choongwae Pharma Co. transfer new medicine on $ 7 million
Choongwae-Japan' Jugai ,
Transfer of technical know-how under contract
Choongwae Pharma Co. announced that the rights of the new medicine proposed mat...
R&D commission for bio-engineering newly set up.
In the KPMA directorate meeting on March 6 they decided to establish "R&D Commission for Bio-engineering" for the development of bio-engineering science in the 21th century with the objectives of playing as a pioneer ...
Paclitaxel oral dosage form soon available.
Hanmi Pharmaceutical company announced on Sept. 19 that an oral dosage form of Paclitaxel, an excellent anticancer agent, had been successfully developed for the first time over the world under a close research cooper...
Macrogen to succeed in discovering Zymomonas nucleotide sequence.
Macrogen (President: Mr. Suh Jung-sun), a bio-engineering venture business company in Korea, has finally succeeded in discovering the nucleotide base sequence of Zymomonas Mobilis' genome (an alcohol fermenting strain...
NF-kB, a transcription factor, studied for an anticancer effect.
A study report attracts many interests, covering that NF-kB, a transcription factor, may physiologically eradicate cancer cells, which suggested a possibility of utilizing it for a new cancer drug. The report was pres...
R&D cost to be reflected in insurance drug prices.
For the international competitiveness in the pharmaceutical industry to be enhanced and its leading role in the national economy of 21th century to be fostered, the KPMA raised several issues during an interview with ...
"New Chemical Compound Bank" to establish for new drug R&D.
The Industrial Technology Research Society established the New Chemical Compound Bank of Korea in the Korea Chemical Research Institute initially with 600 million won of investment and further 5 billion won to put in ...
R&D cost reflected to medical insurance drug prices
In the top executive meeting of the KPMA it was agreed that the R&D cost for a new drug development should be reflected to the medical drug insurance price so that the company could return their heavy investment as ea...
Daesang company fully committed major investment for bio-science industry.
Daesang company (Chairman: Ko Doo-mo) announced in the meeting of the Bio-Science Commission (Head commissioner: Lim Bun-sang, the vice president of Daesang) at the Central Research Laboratory located in Iechon, Kyung...
